title: Early lymphoid lesions: conceptual, diagnostic and clinical challenges.
abstract: There are no "benign lymphomas", a fact due to the nature of lymphoid cells to circulate and home as part of their normal function. Thus, benign clonal expansions of lymphocytes are only rarely recognized when localized. Recent studies have identified a number of lymphoid proliferations that lie at the interface between benign and malignant. Some of these are clonal proliferations that carry many of the molecular hallmarks of their malignant counterparts, such as BCL2/IGH and CCND1/IGH translocations associated with the in situ forms of follicular lymphoma and mantle cell lymphoma, respectively. There are other clonal B-cell proliferations with low risk of progression; these include the pediatric variants of follicular lymphoma and marginal zone lymphoma. Historically, early or incipient forms of T/NK-cell neoplasia also have been identified, such as lymphomatoid papulosis and refractory celiac disease. More recently an indolent form of T-cell lymphoproliferative disease affecting the gastrointestinal tract has been described. Usually, CD8(+), the clonal cells are confined to the mucosa. The clinical course is chronic, but non-progressive. NK-cell enteropathy is a clinically similar condition, composed of cytologically atypical NK-cells that may involve the stomach, small bowel or colon. Breast implant-associated anaplastic large cell lymphoma is a cytologically alarming lesion that is self-limited if confined to the seroma cavity. Atypical lymphoid proliferations that lie at the border of benign and malignant can serve as instructive models of lymphomagenesis. It is also critical that they be correctly diagnosed to avoid unnecessary and potentially harmful therapy.
authors.affiliation: Hematopathology Section, Center for Cancer Research, Laboratory of Pathology, National Cancer Institute, Harvard Medical School, Boston, USA.
authors.forename: Karthik A
authors.initials: KA
authors.lastname: Ganapathi
authors.affiliation: Hematopathology Section, Center for Cancer Research, Laboratory of Pathology, National Cancer Institute, Harvard Medical School, Boston, USA.
authors.forename: Stefania
authors.initials: S
authors.lastname: Pittaluga
authors.affiliation: Center for Hematologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
authors.forename: Oreofe O
authors.initials: OO
authors.lastname: Odejide
authors.affiliation: Center for Hematologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
authors.forename: Arnold S
authors.initials: AS
authors.lastname: Freedman
authors.affiliation: Hematopathology Section, Center for Cancer Research, Laboratory of Pathology, National Cancer Institute, Harvard Medical School, Boston, USA ejaffe@mail.nih.gov.
authors.forename: Elaine S
authors.initials: ES
authors.lastname: Jaffe
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology*; D015415:Biomarkers / Q000378:metabolism; D049109:Cell Proliferation; D002999:Clone Cells; D042241:Early Diagnosis; D015870:Gene Expression; D006801:Humans; D016130:Immunophenotyping; D008223:Lymphoma / Q000145:classification / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology*; D014178:Translocation, Genetic
chemical_list: D015703:Antigens, CD; D000970:Antineoplastic Agents; D015415:Biomarkers